INVESTOR ALERT: Class Action Lawsuit Filed on Behalf of Aldeyra Therapeutics, Inc. (ALDX) ...

{{author}}
A class action lawsuit alleges Aldeyra Therapeutics misled investors regarding inconsistent clinical trial results for reproxalap.

Summary

A shareholder class action lawsuit has been filed against Aldeyra Therapeutics, Inc. (NASDAQ: ALDX). The suit claims Aldeyra issued false or misleading statements, or failed to disclose critical information, concerning its business, operations, and future prospects. Specifically, the lawsuit alleges that the results from clinical trials of reproxalap were inconsistent, and that these inconsistencies made any positive findings from the trials unreliable and without merit. Investors who purchased Aldeyra shares between November 3, 2023, and March 16, 2026, and experienced a significant loss are encouraged to contact Corey D. Holzer, Esq. at [email protected] or call (888) 508-6832 for information about their legal rights.

(Source:{{author}})